Speech-Language Pathologists in Rushville, IN Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Mrs. Rya M Meo, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 341 W 10th St, Rushville, IN 46173 Phone: 765-938-1042

Susan Spaeth Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3818 S 400 W, Rushville, IN 46173 Phone: 864-630-0409

Deborah Sue Manlief, M.A.,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3805 E State Road 244, Rushville, IN 46173 Phone: 765-629-2733

Rebecca Wilcher Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 612 E 11th St, Rushville, IN 46173 Phone: 765-932-4127

News Archive

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.

Study evaluates frequency and features of very large treatment effects of medical interventions

In an examination of the characteristics of studies that yield large treatment effects from medical interventions, these studies were more likely to be smaller in size, often with limited evidence, and when additional trials were performed, the effect sizes became typically much smaller, according to a study in the October 24/31 issue of JAMA.

Linkwell to acquire Metamining Nevada

Linkwell Corporation, a developer, manufacturer and distributer of disinfectant healthcare products in China, announced today it has entered into a definitive share exchange agreement with Metamining Inc. to acquire Metamining Nevada, Inc., as a wholly owned subsidiary,

Health Canada approves GARDASIL for prevention of genital warts in males

Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.

Hawaii surgeons successfully implant FDA-approved eye telescope for AMD

A team of surgeons from Hawaii, Dr. Michael Bennett of Retina Institute of Hawaii and Dr. Michael McMann of McMann Institute, has successfully implanted the FDA-approved eye telescope, a first in Hawaii, at one of the leading medical centers in Honolulu.

Read more Medical News

› Verified 2 days ago